Bahçeşehir University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye
Medical Park Göztepe Hospital, Adult Hematology and Bone Marrow Transplantation Unit, İstanbul, Türkiye
Turk J Haematol. 2024 Aug 28;41(3):182-187. doi: 10.4274/tjh.galenos.2024.2024.0099. Epub 2024 May 27.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a widely utilized treatment for various hematological diseases. While selection criteria for unrelated donors are well established, there is a lack of consistency and standardization in the selection of related donors. This study investigated the current approach of hematologists to the selection of related donors at Turkish HSCT centers. The study employed a cross-sectional survey design, distributing a self-administered questionnaire to 95 adult and pediatric transplantation centers in Türkiye to investigate their approaches to related donor selection for allo-HSCT. The questionnaire collected data on various topics including the center’s experience in performing allo-HSCT, patient groups treated, number of allo-HSCT procedures conducted between 2015 and 2021, preferences for related donors, considerations in related donor selection (such as sex and past pregnancies), guidelines utilized for related donor selection, upper age limit for related donors, and the use of specialized advanced analyses for elderly donors. The response rate to the survey was 38.9%. Variability was observed across centers in terms of sex consideration and the impact of past pregnancies on related female donor rejection. Different guidelines were employed for related donor selection, with the European Bone Marrow Transplantation guidelines being the most commonly used. Regarding the upper age limit for related donors, 8.1% of centers accepted an upper age limit of 55 years, 48.7% preferred an upper age limit of 65 years, and 43.2% selected related donors aged 65 and above. The lack of standardized guidelines for related donor selection in HSCT centers leads to variability in criteria and potential risks. Collaboration among centers is essential to establish consensus and develop standardized protocols.
异基因造血干细胞移植（allo-HSCT）是治疗各种血液疾病的广泛应用的方法。虽然无关供者的选择标准已经确立，但在相关供者的选择方面缺乏一致性和标准化。本研究调查了土耳其 HSCT 中心的血液科医生目前选择相关供者的方法。该研究采用横断面调查设计，向土耳其的 95 个成人和儿科移植中心分发了一份自我管理问卷，以调查他们对 allo-HSCT 相关供者选择的方法。该问卷收集了各种主题的数据，包括中心进行 allo-HSCT 的经验、治疗的患者群体、2015 年至 2021 年期间进行的 allo-HSCT 程序数量、对相关供者的偏好、相关供者选择的考虑因素（如性别和过去的怀孕）、用于相关供者选择的指南、相关供者的上限年龄以及对老年供者使用专门的先进分析。该调查的回复率为 38.9%。各中心在性别考虑和过去怀孕对相关女性供者拒绝的影响方面存在差异。不同的指南用于相关供者的选择，欧洲骨髓移植指南是最常用的。关于相关供者的上限年龄，8.1%的中心接受 55 岁的上限年龄，48.7%的中心更喜欢 65 岁的上限年龄，43.2%的中心选择 65 岁及以上的相关供者。HSCT 中心缺乏相关供者选择的标准化指南导致标准的差异和潜在风险。中心之间的合作对于建立共识和制定标准化方案至关重要。
